Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Acceleron Pharma Inc. XLRN
$178.75
На 18:00, 12 мая 2023
-13.40%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
189.99
-
week52low
111.75
-
Revenue
92523000
-
P/E TTM
-61
-
Beta
0.13142800
-
EPS
0.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 ноя 2021 г. в 04:00
Описание компании
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Hold | 07 окт 2021 г. | |
| Raymond James | Market Perform | Strong Buy | 04 окт 2021 г. |
| Morgan Stanley | Equal-Weight | Overweight | 01 окт 2021 г. |
| Barclays | Equal-Weight | Overweight | 01 окт 2021 г. |
| SVB Leerink | Market Perform | Outperform | 23 мар 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Zakrzewski Joseph S | D | 0 | 3222 | 19 ноя 2021 г. |
| Zakrzewski Joseph S | D | 0 | 34499 | 19 ноя 2021 г. |
| Malik Kemal | D | 0 | 3222 | 19 ноя 2021 г. |
| Malik Kemal | D | 0 | 1622 | 19 ноя 2021 г. |
| Hite Christopher | D | 0 | 1848 | 19 ноя 2021 г. |
| Hite Christopher | D | 0 | 930 | 19 ноя 2021 г. |
| Smith Karen L. | D | 0 | 3222 | 19 ноя 2021 г. |
| Smith Karen L. | D | 0 | 1622 | 19 ноя 2021 г. |
| Kearney Terrence C | D | 0 | 3222 | 19 ноя 2021 г. |
| Kearney Terrence C | D | 0 | 6749 | 19 ноя 2021 г. |
Новостная лента
Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout
Investors Business Daily
10 окт 2022 г. в 09:49
Merck stock jumped Monday after a drug its acquired for billions scored a "must-win" in patients with a rare blood pressure condition. The post Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout appeared first on Investor's Business Daily.